Symposium Session Topics

Immunotherapy: Immunotherapy has led to significant improvements in cancer treatment and survival compared to conventional cancer therapies (e.g., surgery, radiation, chemotherapy). Clinically validated and increasingly commonly, we will discuss the progress made, and the challenges and potential ahead.

Targeted Cellular Therapies: Engineering a patient’s own immune cells to attack cancer has been transformative for cancer treatment. This session will focus on cell therapies successes, FDA approvals, current clinical trials, and overcoming challenges of using targeted engineered cells for solid tumors.

Targeted new therapies: To include biologics and small molecules and combination approaches that are most promising new developments for hematological and solid tumors

Predictive biomarkers: Development of predictive biomarkers has the potential to determine which treatment, or combination of treatments, will be effective for a particular patient. This session will address the progress made in predictive and biomarkers, as well as how companies with large databases of genetic sequencing and molecular profiles will collaborate with researchers to lead to high-impact research.

Genomics and Computational Cancer Biology: Innovations in high-throughput data analysis and advances in computational cancer biology makes possible the screening of large-scale omics data for potential target ligands and genetic mutations, with implications for cancer drug development and personalized treatments.

Progress and challenges for targeting RNA in Oncology: Recent technological advances have shown that RNA can be effectively targeted. This session will focus on current developments of targeting RNA for cancer treatment.

Trends in Cancer Research: Our forward-thinking experts will discuss cutting-edge new perspectives and technological advances that may be the future of cancer research.